Navigation Links
RSV Researcher Makes Gains in Finding Treatments
Date:4/10/2008

MEMPHIS, Tenn., April 10 /PRNewswire-USNewswire/ -- Leading RSV investigator Dr. John DeVincenzo has taken another step toward finding effective treatment for the disease that causes bronchiolitis and pneumonia according to the Centers for Disease Control. RSV, or respiratory syncytial virus -- is the leading cause of hospitalization of infants in the US and one of the leading causes of viral death in this age group.

DeVincenzo is using the process of RNAi to target RSV. Clinical trials of ALN-RSV01, a treatment that applies new RNA processing discoveries, have demonstrated that the drug was safe and had statistically significant anti-viral activity in experimentally infected adults. The treatment showed a reduced infection rate from approximately 70 percent to 40 percent and doubled the number of uninfected subjects.

"ALN-RSV01 offers a potential new therapeutic approach for the treatment of RSV infection, a serious respiratory viral disease that leads to the hospitalization of nearly 300,000 pediatric and adult patients annually in the U.S. alone," said DeVincenzo.

DeVincenzo, an investigator at the Children's Foundation Research Center located at Le Bonheur Children's Medical Center and the University of Tennessee, is attempting to develop the first human therapeutic that uses the 2006 Nobel Prize winning discovery of RNA interference, or RNAi. "Harnessing RNA interference could be used to conceptually treat many diseases," DeVincenzo said. "RNA interference can theoretically block the production of any disease-causing protein."

Thus, its potential application includes blocking oncogenic proteins that cause cancer and applications to other diseases as wide-ranging as genetic diseases such as cystic fibrosis and other common diseases such as cardiovascular disease.

DeVincenzo's RSV study is the first definitive proof that RNA-interference-based therapeutics can work in humans. He is working with Alnylam Pharmaceuticals to develop the treatment and presented the complete results of the study at the International Symposium on Respiratory Viral Infections meeting in Singapore in early March.

The clinical trial, named GEMINI, was a double-blind, placebo-controlled, randomized study of ALN-RSV01 in 88 healthy adult subjects experimentally infected with a wild-type clinical strain of RSV developed and manufactured from one of DeVincenzo's study patients at Le Bonheur. DeVincenzo's GEMINI study's results and their potential impact on human health were reviewed in the Wall Street Journal in early March.

The next stage in developing the treatment will be to conduct Phase II trials in naturally infected adult patients. Subsequent studies involving children are being planned.

Founded in 1952, Le Bonheur Children's Medical Center is the Mid-South's first and only comprehensive pediatric medical facility. Every year Le Bonheur treats almost 140,000 children from 47 states and many countries. Le Bonheur is home to one of the nation's 10 busiest pediatric emergency departments and hosts one of the largest pediatric surgical brain tumor programs.

Le Bonheur is currently in the midst of a fundraising campaign to build a new state-of-the art hospital. The $327-million facility is scheduled to open in 2010 and will double the space for patient care, research and teaching. For more information, please call (901) 287-6030 or visit http://www.lebonheur.org.

Available Topic Expert(s): For information on the listed expert(s), click appropriate link.

Dr. John DeVincenzo

http://profnet.prnewswire.com/Subscriber/ExpertProfile.aspx?ei=75590

Contact:

Anne Glankler

901-287-6030

glanklea@lebonheur.org


'/>"/>
SOURCE Le Bonheur Children's Medical Center
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Researchers at Cleveland Clinic Identify Site of Dysfunction in HDL, Carrier of Good Cholesterol
2. Cleveland Clinic Researchers Identify Mechanism Behind Platelet Function and Potentially Fatal Blood Clot Formation
3. Researchers Identify Virus Possibly Responsible for Declining Honeybee Population Using 454 Sequencing Technology from Roche
4. Peregrine Researchers Report Data Showing Bavituximabs Potential to Shrink Human Prostate Tumors in Model of Relapsed Disease
5. K-State Researchers Bringing Expertise to Kansas City Symposium on Disease and National Security
6. U. of Md. Researchers to Develop Devices to Revolutionize Drug Research
7. 454 Sequencing(TM) in Science Today: Researchers Uncover a Genetic Basis for Different Social Behaviors in Wasps
8. Researchers Report First Successful Treatment of Chronic Traumatic Brain Injury
9. Potential Breakthrough Cancer Treatment Emerges from MIPS-Funded Clinical Trial Teaming CSA Medical Inc. and University of Maryland Researchers
10. Researchers Develop New Procedure to Screen All 46 Human Chromosomes to Identify Abnormalities in Embryos
11. Honor Society of Nursing Recognizes Researcher of HIV Risk Prevention for Poor and Underserved
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/5/2016)... Colo. , Nov. 29, 2016 Several ... hosted by Accera, Inc. at 11 a.m. ... Annual International Conference on Clinical Trials for Alzheimer,s Disease ... of metabolism in Alzheimer,s disease and therapeutic targets that ... "Following the recent failure of another therapy ...
(Date:12/5/2016)... 5, 2016 Research and Markets has ... (Instruments, Consumables), Application (Biomedical & Biochemical Research, Disease Diagnostics), End User ... to 2021" report to their offering. ... , , ... in 2021 from USD 574.8 Million in 2016, growing at a ...
(Date:12/5/2016)... PUNE, India , December 5, 2016 According to ... Product Type and by Application - Global Opportunity Analysis and Industry Forecast, 2014 ... and is expected to reach $5,255 million by 2022, growing at a CAGR ... 2015 with more than four-fifths share. Continue Reading ... ...
Breaking Medicine Technology:
(Date:12/5/2016)... ... December 05, 2016 , ... "FCPX Overlay Glare is a tool ... effect without heavy rendering or complicated compositing," said Christina Austin - CEO of Pixel ... an organic spectrum of lights that simulates the look of a glare. Just ...
(Date:12/5/2016)... ... December 06, 2016 , ... For many years, Andrew G. ... thick and thin. The beauty of the Lithuanian language and its poetry ... this poetry book, Zubinas lyrically explores all aspects of a living, breathing forest where ...
(Date:12/5/2016)... ... 2016 , ... Researchers at Johns Hopkins All Children’s Hospital want to learn ... the course of three years, researchers will study concussions and changes in brain function ... with special sensors, will track the location and force of the hit. The sensors ...
(Date:12/5/2016)... , ... December 05, 2016 , ... ... a patent-pending blend of L-Citrulline and glutathione to enhance production of nitric oxide ... that studies have shown to produce NO twice as effectively and sustains NO ...
(Date:12/5/2016)... , ... December 05, 2016 , ... ... and geographic lines. The goal of Castlewood Treatment Centers has always been to ... accessible to as many people as possible. In that spirit, Castlewood has announced ...
Breaking Medicine News(10 mins):